pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

329 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT977Endpoints750BioPharma Dive287BioSpace188Fierce Biotech180onclive165globenewswire health73raps66
therapy area
allOncology5730Rare Disease1265Cardiology1064Immunology961Hematology952Pulmonology845Vaccines826Psychiatry & CNS698
  • Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors
    Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors.
    onclive · 3mo ago↗ source
  • New subpoena suggests DOJ has begun criminal investigation of gender-affirming care
    Several hospitals have received federal grand jury subpoenas regarding gender-affirming care for minors, suggesting a criminal investigation has begun.
    STAT · 3mo ago↗ source
  • UCSF Receives Major Gift to Advance Research and Modernization
    Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.
    onclive · 3mo ago
← prev
page 9 of 14
next →
fda recalls41
fda medwatch32
fda press25
Ophthalmology371
Pain344
Endocrinology & Metabolism343
Infectious Disease334
↗ source
  • CLL-321 Trial Efficacy and Safety Results Analysis
    Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.
    onclive · 3mo ago↗ source
  • How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCO
    Drs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.
    onclive · 3mo ago↗ source
  • BRUIN CLL-321 Trial Impact and Treatment Selection
    Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.
    onclive · 3mo ago↗ source
  • Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy
    Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.
    onclive · 3mo ago↗ source
  • Extreme heat is worsening faster for Black Americans
    Bill Cassidy's can't-win conundrum, what RFK Jr. gets right and wrong about antidepressants, and more health news
    STAT · 3mo ago↗ source
  • Opinion: RFK Jr.’s antidepressant deprescribing push gets one thing right — and others dangerously wrong
    “Deprescribing requires gradual tapering, psychological support, careful risk stratification, and accessible alternatives — none of which Kennedy’s initiative provides at scale.”
    STAT · 3mo ago↗ source
  • Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
    Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
    onclive · 3mo ago↗ source
  • Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
    Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
    onclive · 3mo ago↗ source
  • Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma
    Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.
    onclive · 3mo ago↗ source
  • Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma
    Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.
    onclive · 3mo ago↗ source
  • Males who discuss suicide seek help less often than females, report finds
    Out of 1.5 million messages received in 2025, the Crisis Text Line found that less then 20% of the texters identified as male only
    STAT · 3mo ago↗ source
  • Supreme Court extends mifepristone deadline
    The deadliest drug in the country, the new name for PCOS, and more health news from Morning Rounds
    STAT · 3mo ago↗ source
  • Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
    A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.
    onclive · 3mo ago↗ source
  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 3mo ago↗ source
  • Unmet Needs in Endometrial Cancer
    Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.
    onclive · 3mo ago↗ source
  • EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs
    In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that…
    onclive · 3mo ago↗ source
  • Future Directions in Relapsed and Refractory Multiple Myeloma
    onclive · 3mo ago↗ source
  • Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
    Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.
    onclive · 3mo ago↗ source
  • Sequencing Strategies After Progression in Multiple Myeloma
    onclive · 3mo ago↗ source
  • EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy
    In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.
    onclive · 3mo ago↗ source
  • Sequencing ADCs in Endometrial Cancer
    Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.
    onclive · 3mo ago↗ source
  • Second Clinical Scenario - Progressive Disease Despite Hematocrit Control
    Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.
    onclive · 3mo ago↗ source